Research menu
Jump to menu

Publications:  Dr Gareth Pryce

Saxena G, Moore JM, Jones M, Pryce G, Ali L, Leisegang GR, Vijay V, Loveless S et al.(2020). Detecting and predicting neutralization of alemtuzumab responses in MS. Neurology(R) neuroimmunology & neuroinflammation vol. 7, (4)
Baker D, Pryce G, James LK, Marta M, Schmierer K(2020). The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders Article 102279, 102279-102279.
Baker D, Ali L, SAXENA G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S et al.(2020). The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies. Frontiers in Immunology vol. 11, (124)
Baker D, Pryce G, James LK, Schmierer K, Giovannoni G(2020). Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. European Journal of Neurology vol. 27, (2) 221-228.
Licht-Mayer S, Campbell GR, Canizares M, Mehta AR, Gane AB, McGill K, Ghosh A, Fullerton A et al.(2020). Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. Acta Neuropathologica
Baker D, Pryce G, Herrod SS, Schmierer K(2019). Potential mechanisms of action related to the efficacy and safety of cladribine. Multiple Sclerosis and Related Disorders vol. 30, 176-186.
Pryce G, Baker D(2019). CHAPTER 11: Cannabinoids as a Therapeutic Approach in Multiple Sclerosis. RSC Drug Discovery Series, vol. 2019-January,
BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K(2018). Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain
BO XUENONG, GUSHCHINA S, PRYCE G, YIP P, WU D, PALLIER P, GIOVANNONI G, BAKER D(2018). Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia vol. 66, (10) 2108-2125.
BAKER D, Pryce, G(2018). Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter?. multiple sclerosis and related disorders
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al.(2018). Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology vol. 154, (2) 253-260.
Pryce G, Baker D(2017). Antidote to cannabinoid intoxication: the CB<inf>1</inf> receptor inverse agonist, AM251, reverses hypothermic effects of the CB<inf>1</inf> receptor agonist, CB-13, in mice. British Journal of Pharmacology vol. 174, (21) 3790-3794.
Pryce G, Sisay S, Petrova N, Giovannonni G, Selwood DL, Baker D (2017). Neuroprotection in an experimental model of multiple sclerosis, via opening of big conductance, calcium-activated potassium channels. MULTIPLE SCLEROSIS JOURNAL. vol. 23, 621-622.
BAKER D(2017). Big conductance calcium-activated potassium channel openers control spasticity without sedation. British Journal of Pharmcology
BAKER D, Giovannoni G, Sefia E, Pryce G, Meier U(2017). Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Multiple Sclerosis and Related Disorders
von Kutzleben S, Pryce G, Giovannoni G, Baker D(2017). Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immunetolerance promoting CD8 t-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology vol. 150, (4) 444-455.
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K(2017). Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine vol. 16, 41-50.
Williams T, Pryce G, Giovannoni G, Selwood D, Baker D (2016). VSN16R-A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS. vol. 87, is. 12, Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob ,
Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM et al.(2016). Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice. Immunology vol. 149, (2) 146-156.
Sevastou I, Pryce G, Baker D, Selwood DL(2016). Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing. PLOS ONE vol. 11, (6) e0157754-e0157754.
Ummenthum K, Peferoen LAN, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B et al.(2016). Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease. European Journal of Immunology vol. 46, (3) 701-711.
Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L et al.(2016). Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis. Journal of Biological Chemistry vol. 291, (9) 4356-4373.
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D(2015). Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. Journal of Neuroimmune Pharmacology vol. 10, (2) 281-292.
Pryce G, Baker D(2015). Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis. vol. 231, 213-231.
Pryce G, Baker D(2015). Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis. Evidence-Based Medicine vol. 20, (4)
Vainchtein I, Vinet J, Al-Izki S, Pryce G, Grit C, Brouwer N, Amor S, Baker D et al. (2015). Microglia are involved in apoptotic clearance during chronic-relapsing EAE. GLIA. vol. 63, E353-E353.
Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, Van Der Pol SMA, Hirst MC et al.(2015). Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation. Journal of Cerebral Blood Flow and Metabolism vol. 35, (3) 412-423.
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D(2014). Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. Journal of Neuroimmune Pharmacology
Von Kutzleben S, Pryce G, Chretien N, Turner M, Siders W, Baker D (2014). Inhibition of relapsing experimental autoimmune encephalomyelitis in Biozzi ABH mice using a mouse CD52-specific monoclonal antibody. JOURNAL OF NEUROIMMUNOLOGY. vol. 275, 228-228.
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE et al.(2014). MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. FASEB J vol. 28, (6) 2551-2565.
Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJM, Giovannoni G, Baker D, Chandran S(2014). Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathologica Communications vol. 2, (1)
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A et al.(2014). Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J vol. 28, (1) 117-130.
Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C et al.(2014). Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opin Drug Deliv vol. 11, (1) 5-16.
Al-Izki S, Pryce G, Hankey DJR, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C et al.(2014). Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain vol. 137, (Pt 1) 92-108.
Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G et al.(2013). Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler vol. 19, (14) 1896-1904.
Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferoen-Baert R, Ummenthum K, Pryce G et al.(2013). Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation vol. 10,
Baker D, Lidster K, Al-Izki S, Pryce G, Giovannoni G(2013). Animal models of progressive disability in MS. IRISH JOURNAL OF MEDICAL SCIENCE vol. 182, S5-S6.
Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G et al.(2013). Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One vol. 8, (10)
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, de Vries HE, Hirst MC et al. (2012). Endothelial miR-155 promotes blood brain barrier dysfunction in neuroinflammation. JOURNAL OF NEUROIMMUNOLOGY. vol. 253, 3-4.
Pryce G, Baker D(2012). Potential control of multiple sclerosis by cannabis and the endocannabinoid system. CNS Neurol Disord Drug Targets vol. 11, (5) 624-641.
Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G(2012). Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity vol. 45, (4) 298-303.
Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G(2012). The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple Sclerosis and Related Disorders vol. 1, (2) 64-75.
Hilliard A, Stott C, Wright S, Guy G, Pryce G, Al-Izki S, Bolton C, Giovannoni G(2012). Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. ISRN Neurol vol. 2012,
Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D(2012). Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Multiple Sclerosis and Related Disorders vol. 1, (1) 29-38.
Graves RS, Pryce G, Cabranes A, Fernandez-Ruiz J, Bisogno T, Di Marzo V, Cravatt BF, Michael GJ et al.(2011). Fatty acid amide hydrolase as a target for neuroprotection. MULTIPLE SCLEROSIS JOURNAL vol. 17, S431-S431.
Al-Izki S, Pryce G, Amor S, Gerritsen W, Garthwaite J, Giovannoni G, Selwood DL, Baker D(2011). Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS JOURNAL vol. 17, S209-S210.
Pryce G, Visintin C, Lutz B, Marsicano G, Giovannoni G, Selwood DL, Baker D(2011). Selective targeting of spasticity by CNS-excluded cannabinoids. MULTIPLE SCLEROSIS JOURNAL vol. 17, S247-S247.
Baker D, Pryce G, Visintin C, Pertwee RG, Tanner C, Ross R, Irving A, Sisay S et al.(2011). VSN16R a novel agent for the control of spasticity. MULTIPLE SCLEROSIS JOURNAL vol. 17, S243-S243.
Ayoub SS, Pryce G, Seed MP, Bolton C, Flower RJ, Baker D(2011). Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404. Drug Metab Dispos vol. 39, (9) 1689-1695.
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D(2011). Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler vol. 17, (8) 939-948.
Al-Izki S, Pryce G, Giovannoni G, Baker D(2009). Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography. Mult Scler vol. 15, (7) 795-801.
Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJM et al.(2008). An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J NEUROIMMUNOL vol. 201, 200-211.
Jackson S, Al-Izik S, Pryce G, Giovannoni G, Baker D (2008). Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS. vol. 14, S80-S81.
Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K (2008). High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S86-S87.
Al-Izki S, Pryce G, Jackson S, Giovannoni G, Baker D (2008). Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis. JOURNAL OF NEUROIMMUNOLOGY. vol. 197, 173-173.
Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G et al.(2008). Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. BRAIN vol. 131, 1736-1748.
East E, Gveri¿ D, Baker D, Pryce G, Lijnen HR, Cuzner ML(2008). Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol Appl Neurobiol vol. 34, (2) 216-230.
Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D(2008). Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis. J NEUROIMMUNOL vol. 193, (1-2) 120-129.
Pryce G, Jackson SJ, Baker D(2008). Cannabinoids for the control of multiple sclerosis. Cannabinoids and the Brain,
Baker D, Pryce G(2008). The endocannabinoid system and multiple sclerosis. Curr Pharm Des vol. 14, (23) 2326-2336.
Baker D, Jackson SJ, Pryce G(2007). Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol vol. 152, (5) 649-654.
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD et al.(2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. NAT MED vol. 13, (4) 492-497.
Pryce G, Baker D(2007). Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. BRIT J PHARMACOL vol. 150, (4) 519-525.
Baker D, Croxford JL, Pryce G, Jackson SM, Ledent C, Marsicano G, Lutz B, Giovannoni G et al. (2006). Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis. JOURNAL OF NEUROIMMUNOLOGY. vol. 178, 90-91.
Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J(2006). Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. BRAIN RES vol. 1107, 199-205.
Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L(2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J vol. 20, (7) 1003-+.
Baker D, Pryce G, Croxford JL, Yamamura T (2006). Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitits. CURRENT TOPICS IN NEUROIMMUNOLOGY. Editors: Tabira, T, Yamamura, T, Kira, J, 109-116.
Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V(2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. NEUROSCIENCE vol. 139, (4) 1405-1415.
Baker D, Pryce G, Davies WL, Hiley CR(2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci vol. 27, (1) 1-4.
Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A et al.(2006). New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. BRIT J PHARMACOL vol. 147, (1) 83-91.
de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA(2006). UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. EUR NEUROPSYCHOPHARM vol. 16, (1) 7-18.
Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AVJ, 't Hart B, Amor S(2005). Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice. J NEUROIMMUNOL vol. 167, (1-2) 23-33.
East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gveri¿ D(2005). A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol vol. 167, (2) 545-554.
Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D(2005). Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J NEUROIMMUNOL vol. 165, (1-2) 41-52.
Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D(2005). Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience vol. 134, (1) 261-268.
Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, 't Hart B, Baker D et al.(2005). Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice. J NEUROIMMUNOL vol. 164, (1-2) 76-84.
Jackson SJ, Diemel LT, Pryce G, Baker D (2005). Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci. vol. 233, 21-25.
Pryce G, Baker D(2005). Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci vol. 28, (5) 272-276.
Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D, Adamson P, Calder V et al.(2005). Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J IMMUNOL vol. 174, (4) 2327-2335.
Pryce G, Jackson SM, Hankey DRJ, Giovannoni G, Baker D (2004). Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 78-78.
Pryce G, O'Neill JK, Hankey DRJ, East E, Amor S, Giovannoni G, Baker B (2004). Immunological tolerance that eliminates relapses, fails to halt secondary progression in a chronic multiple sclerosis model. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 62-62.
Baker D, Pryce G(2004). The potential role of the endocannabinoid system in the control of multiple scleorsis. Current Medicinal Chemistry - Central Nervous System Agents vol. 4, (3) 195-202.
East E, Baker D, Pryce G, Cuzner ML, Gveric D (2004). The role of plasminogen activators in experimental allergic encephalomyelitis: inflammation and axonal pathology. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 167-167.
de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D et al.(2004). In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. EUR J PHARMACOL vol. 484, (2-3) 249-257.
Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EM(2003). Medicinal cannabis: is Delta(9)-tetrahydrocannabinol necessary for all its effects?. J PHARM PHARMACOL vol. 55, (12) 1687-1694.
Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A et al.(2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. BRAIN vol. 126, 2191-2202.
East E, Baker D, Pryce GM, Cuzner ML, Gveric D (2003). The role of plasminogen activators in experimental allergic encephalomyelitis. GLIA. 40-40.
Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P(2003). Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J vol. 17, (8) 905-907.
Pryce G, Giovannoni G, Baker D(2003). Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice. NEUROSCI LETT vol. 341, (2) 164-166.
Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G(2003). Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol vol. 138, (1-2) 45-48.
Baker D, Pryce G, Giovannoni G, Thompson AJ(2003). The therapeutic potential of cannabis. LANCET NEUROL vol. 2, (5) 291-298.
Baker D, Pryce G(2003). The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs vol. 12, (4) 561-567.
Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML(2002). A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis - Inflammation versus degeneration. AM J PATHOL vol. 161, (5) 1577-1586.
Walters CE, Pryce G, Hankey DJR, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P(2002). Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J IMMUNOL vol. 168, (8) 4087-4094.
Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C et al.(2002). Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. EUR J PHARMACOL vol. 439, (1-3) 83-92.
Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML, Diemel LT(2001). Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol vol. 158, (6) 2127-2138.
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L et al.(2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J vol. 15, (2) 300-302.
Baker D, Pryce G, Ludovic Croxford J, Brown P, Pertwee RG, Huffman JW, Layward L(2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature vol. 404, (6773) 84-87.
Pryce G, Male D, Campbell I, Greenwood J(1997). Factors controlling T-cell migration across rat cerebral endothelium in vitro. Journal of Neuroimmunology vol. 75, (1-2) 84-94.
Greenwood J, Pryce G, Devine L, Male DK, Dos Santos WLC, Calder VL, Adamson P(1996). SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. Journal of Neuroimmunology vol. 71, (1-2) 51-63.
Male D, Rahman J, Pryce G, Tamatani T, Miyasaka M(1994). Lymphocyte migration into the CNS modelled in vitro: Roles of LFA-1, ICAM- 1 and VLA-4. Immunology vol. 81, (3) 366-372.
Pryce G, Santos W, Male D(1994). An assay for the analysis of lymphocyte migration across cerebral endothelium in vitro. Journal of Immunological Methods vol. 167, (1-2) 55-63.
Male D, Pryce G, Linke A, Rahman J(1992). Lymphocyte migration into the CNS modelled in vitro. Journal of Neuroimmunology vol. 40, (2-3) 167-171.
Pryce G, Male DK, Sarkar C(1991). Control of lymphocyte migration into brain: Selective interactions of lymphocyte subpopulations with brain endothelium. Immunology vol. 72, (3) 393-398.
Male D, Pryce G, Hughes C, Lantos P(1990). Lymphocyte migration into brain modelled in vitro: Control by lymphocyte activation, cytokines, and antigen. Cellular Immunology vol. 127, (1) 1-11.
Male D, Pryce G, Rahman J(1990). Comparison of the immunological properties of rat cerebral and aortic endothelium. Journal of Neuroimmunology vol. 30, (2-3) 161-168.
Pryce G, Male D, Sedgwick J(1989). Antigen presentation in brain: Brain endothelial cells are poor stimulators of T-cell proliferation. Immunology vol. 66, (2) 207-212.
Male D, Pryce G(1989). Induction of Ia molecules on brain endothelium is related to susceptibility to experimental allergic encephalomyelitis. Journal of Neuroimmunology vol. 21, (1) 87-90.
Male D, Pryce G(1988). Kinetics of MHC gene expression and mRNA synthesis in brain endothelium. Immunology vol. 63, (1) 37-42.
Male D, Pryce G(1988). Synergy between interferons and monokines in MHC induction on brain endothelium. Immunology Letters vol. 17, (3) 267-271.
Male DK, Pryce G, Hughes CCW(1987). Antigen presentation in brain: MHC induction on brain endothelium and astrocytes compared. Immunology vol. 60, (3) 453-459.
Male DK, Pryce G, Butcher GW(1987). SEROLOGICAL EVIDENCE FOR A DEFECT IN RT1.B (I‐A) EXPRESSION BY THE BDIX RAT STRAIN. International Journal of Immunogenetics vol. 14, (6) 301-312.
Banga JP, Mirakian R, Hammond L, Pryce G, Bidey S, Bottazzo F, Weetman AP, McGregor AM et al.(1986). Characterization of monoclonal antibodies directed towards the microsomal/microvillar thyroid autoantigen recognized by Hashimoto autoantibodies. Clinical and Experimental Immunology vol. 64, (3) 544-554.
Male D, Pryce G(1986). Agglutination Assay Using Protein A-Sensitized Erythrocytes for Detection of Immunoglobulin in Tissue Culture Supernatants. Methods in Enzymology vol. 121, (C) 556-561.
MALE DK, PRYCE G, COOKE A, HUTCHINGS P, MARSHALL S, ROITT IM(1986). T and B Cell Connections in Experimentally Induced Autoimmunity. Annals of the New York Academy of Sciences vol. 475, (1) 94-105.
Male D, Lelchuk R, Curry S, Pryce G, Playfair JH(1985). Serum IL-2 inhibitor in mice. II. Molecular characteristics. Immunology vol. 56, (1) 119-125.
Male DK, Champion BR, Pryce G, Matthews H, Shepherd P(1985). Antigenic determinants of human thyroglobulin differentiated using antigen fragments. Immunology vol. 54, (3) 419-427.
Male D, Pryce G, Roitt I(1985). Molecular analysis of induced idiotypes associated with autoanti-thyroglobulin. Molecular Immunology vol. 22, (3) 255-263.
Banga JP, Pryce G, Hammond L, Roitt IM(1985). Structural features of the autoantigens involved in thyroid autoimmune disease: The thyroid microsomal/microvillar antigen. Molecular Immunology vol. 22, (6) 629-642.
BANGA JP, GUARNOTTA G, HARTE A, PRYCE G, CAMPBELL MA, QUARTEY¿PAPAFIO R, LYDYARD PM, ROITT IM(1984). A Common Epitope Identified by a Monoclonal Antibody, MID 2, Present on All Leucocytes and Associated with a Group of High Molecular Weight Glycopeptides. Scandinavian Journal of Immunology vol. 19, (1) 11-21.
Banga JP, Pryce G, Hammond L, Roitt IM(1984). Characterization of the human thyroid microsomal antigen involved in thyroid autoimmunity. Biochemical Society Transactions vol. 12, (6) 1118-1119.
Male D, Pryce G(1983). A rapid assay for immunoglobulin in hybridoma supernatants. Immunological Investigations vol. 12, (5) 465-471.
Male D, Pryce G, Quartey¿Papafio R, Roitt I(1983). The occurrence of defined idiotypes on autoantibodies to mouse thyroglobulin. European Journal of Immunology vol. 13, (11) 942-947.
Return to top